MedTrace Logo

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

NCT01114672 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-02-21

Study results available
· View outcomes & findings →

Summary

Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective.

Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients.

The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.

Conditions

  • Pruritis

Interventions

DRUG

50,000 Units Ergocalciferol

50,000 Units oral ergocalciferol to be given once weekly

DRUG

Placebo

oral placebo once weekly

Sponsors & Collaborators

  • National Kidney Foundation, United States

    collaborator OTHER

  • Winthrop University Hospital

    lead OTHER

Principal Investigators

  • Steven Fishbane, MD · Department of Nephrology, Winthrop Univ Hospital

  • Mary Schanler, MS, RD · Winthrop University Hospital, Outpatient Dialysis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-11-30
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114672 on ClinicalTrials.gov